Pondé, N., Aftimos, P., & Piccart, M. (2019). Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review. Current Treatment Options in Oncology, 20(5), 37. https://doi.org/10.1007/s11864-019-0633-6

Article  PubMed  Google Scholar 

Tang, S. C., Capra, C. L., Ajebo, G. H., et al. (2021). Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer. International Journal of Cancer, 149(4), 909–916. https://doi.org/10.1002/ijc.33597

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hafeez, U., Parakh, S., Gan, H. K., & Scott, A. M. (2020). Antibody-Drug Conjugates for Cancer Therapy. Molecules Basel Switz, 25(20), 4764. https://doi.org/10.3390/molecules25204764

Article  CAS  Google Scholar 

Staudacher, A. H., & Brown, M. P. (2017). Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required? British Journal of Cancer, 117(12), 1736–1742. https://doi.org/10.1038/bjc.2017.367

Article  CAS  PubMed  PubMed Central  Google Scholar 

Su, Z., Xiao, D., Xie, F., et al. (2021). Antibody–drug conjugates: Recent advances in linker chemistry. Acta Pharmaceutica Sinica B, 11(12), 3889–3907. https://doi.org/10.1016/j.apsb.2021.03.042

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsuchikama, K., Anami, Y., Ha, S. Y. Y., & Yamazaki, C. M. (2024). Exploring the next generation of antibody–drug conjugates. Nature Reviews Clinical Oncology, 21(3), 203–223. https://doi.org/10.1038/s41571-023-00850-2

Article  CAS  PubMed  Google Scholar 

Lonial, S., Lee, H. C., Badros, A., et al. (2021). Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer, 127(22), 4198–4212. https://doi.org/10.1002/cncr.33809

Article  CAS  PubMed  Google Scholar 

Pro, B., Advani, R., Brice, P., et al. (2012). Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(18), 2190–2196. https://doi.org/10.1200/JCO.2011.38.0402

Article  CAS  PubMed  Google Scholar 

Younes, A., Gopal, A. K., Smith, S. E., et al. (2012). Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30(18), 2183–2189. https://doi.org/10.1200/JCO.2011.38.0410

Article  CAS  PubMed  Google Scholar 

Horwitz, S. M., Advani, R. H., Bartlett, N. L., et al. (2014). Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood, 123(20), 3095–3100. https://doi.org/10.1182/blood-2013-12-542142

Article  CAS  PubMed  PubMed Central  Google Scholar 

Monjanel, H., Deville, L., Ram-Wolff, C., et al. (2014). Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. British Journal of Haematology, 166(2), 306–308. https://doi.org/10.1111/bjh.12849

Article  CAS  PubMed  Google Scholar 

Duvic, M., Tetzlaff, M. T., Gangar, P., Clos, A. L., Sui, D., & Talpur, R. (2015). Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. Journal of Clinical Oncology, 33(32), 3759–3765. https://doi.org/10.1200/JCO.2014.60.3787

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, Y. H., Tavallaee, M., Sundram, U., et al. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of Clinical Oncology, 33(32), 3750–3758. https://doi.org/10.1200/JCO.2014.60.3969

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prince, H. M., Kim, Y. H., Horwitz, S. M., et al. (2017). Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): An international, open-label, randomised, phase 3, multicentre trial. The Lancet Lond Engl, 390(10094), 555–566. https://doi.org/10.1016/S0140-6736(17)31266-7

Article  CAS  Google Scholar 

Walewski, J., Hellmann, A., Siritanaratkul, N., et al. (2018). Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. British Journal of Haematology, 183(3), 400–410. https://doi.org/10.1111/bjh.15539

Article  CAS  PubMed  Google Scholar 

Stefoni, V., Marangon, M., Re, A., et al. (2020). Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: A phase II study of FIL ONLUS. Haematologica, 105(10), e512. https://doi.org/10.3324/haematol.2019.243170

Article  PubMed  PubMed Central  Google Scholar 

Kuruvilla, J., Ramchandren, R., Santoro, A., et al. (2021). Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study. The Lancet Oncology, 22(4), 512–524. https://doi.org/10.1016/S1470-2045(21)00005-X

Article  CAS  PubMed  Google Scholar 

Song, Y., Guo, Y., Huang, H., et al. (2021). Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Expert Review of Hematology, 14(9), 867–875. https://doi.org/10.1080/17474086.2021.1942831

Article  CAS  PubMed  Google Scholar 

Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., et al. (2019). Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37(29), 2592–2600. https://doi.org/10.1200/JCO.19.01140

Article  CAS  PubMed  Google Scholar 

Powles, T., Rosenberg, J. E., Sonpavde, G. P., et al. (2021). Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. New England Journal of Medicine, 384(12), 1125–1135. https://doi.org/10.1056/NEJMoa2035807

Article  CAS  PubMed  Google Scholar 

Yu, E. Y., Petrylak, D. P., O’Donnell, P. H., et al. (2021). Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trial. The Lancet Oncology, 22(6), 872–882. https://doi.org/10.1016/S1470-2045(21)00094-2

Article  CAS  PubMed  Google Scholar 

Taksin, A. L., Legrand, O., Raffoux, E., et al. (2007). High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group. Leukemia, 21(1), 66–71. https://doi.org/10.1038/sj.leu.2404434

Article  CAS  PubMed  Google Scholar 

Amadori, S., Suciu, S., Selleslag, D., et al. (2016). Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. Journal of Clinical Oncology, 34(9), 972–979. https://doi.org/10.1200/JCO.2015.64.0060

Article  CAS  PubMed  Google Scholar 

Kantarjian, H., Thomas, D., Jorgensen, J., et al. (2013). Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer, 119(15), 2728–2736. https://doi.org/10.1002/cncr.28136

Article  CAS  PubMed  Google Scholar 

Kantarjian, H. M., DeAngelo, D. J., Stelljes, M., et al. (2019). Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer, 125(14), 2474–2487. https://doi.org/10.1002/cncr.32116

Article  CAS  PubMed  Google Scholar 

Caimi, P. F., Ai, W., Alderuccio, J. P., et al. (2021). Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology, 22(6), 790–800. https://doi.org/10.1016/S1470-2045(21)00139-X

Article  CAS  PubMed